Delcath Systems Announces Successful Exercise of Series E and E1 Warrants Resulting in $16.3 Million Funding

Delcath Systems, Inc. announces successful warrant exercise bringing in $16.3 million in funding and expresses confidence in commercialization efforts and clinical development. Delcath's HEPZATO KIT and CHEMOSAT focus on delivering high-dose chemotherapy to the liver while managing systemic exposure and associated side effects during a PHP procedure.